ITZ-1 is an orally active and selective extracellular signal-regulated kinase (ERK)-mitogen-activated protein kinase (MAPK) pathway inhibitor with an IC50 of 0.51 µM for inhibiting interleukin-1beta (IL-1beta)-induced matrix metalloproteinase-13 (MMP-13) production. ITZ-1 reduces MMP-13 expression and suppresses nitric oxide (NO)-induced chondrocyte apoptosi. ITZ-1 is promising for research of osteoarticular diseases[1].
Molecular Weight:
541.58
CAS Number:
[1180532-17-5]
Formula:
C20H20F5N3O3S3
Target:
ERK,p38 MAPK
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
